Ebola cases have been detected in two additional health zones in the Democratic Republic of the Congo, including border areas of South Ubangi and Haut-Uele. Health workers are struggling to contain the spread.
6:16 PMAl Jazeera25 stories from 10 sources
Healthcare advances as outbreaks and policy shifts raise the stakes
Day’s Recap
Supporting Articles
The opinion argues that FDA commissioner nominee Heidi Overton is mishandling the scientific evidence surrounding mifepristone. It frames her appointment as placing new leadership over a long-running dispute about the abortion medication.
10:39 AMStat News
The roundup covers Senate questioning of President Trump’s FDA commissioner nominee on China, vaccines, and abortion access. It also points to a Novo Nordisk deal and other health policy and pharmaceutical news.
9:32 AMStat News
A federal judge rolled back landmark protections favoring community-based living and services for people with disabilities. The Justice Department said in June that it would stop enforcing laws that prioritize community settings over nursing homes.
8:53 AMStat News
Novo Nordisk is trying to regain momentum as Eli Lilly strengthens its position in the GLP-1 obesity-drug market. Analysts point to Lilly's advantages as a reason it may remain ahead while Novo seeks a turnaround.
8:51 AMCNBCShares of Swedish drug-delivery company Nanexa rose more than 150% after it announced a licensing agreement with Novo Nordisk. The deal gives Novo access to Nanexa's injectable drug-delivery technology.
5:58 AMCNBC
Novo Nordisk struck a licensing deal valued at more than $1 billion days after its capital-markets day disappointed investors. The agreement sent shares of the Swedish partner sharply higher and offered Novo a new strategic asset.
5:11 AMMarketWatch
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It offers an alternative to daily long-acting insulin injections.
11:25 AMStat News
Researchers edited donor stem cells to remove CD33, a protein also targeted by some blood cancer treatments. In a 30-patient trial, the modified cells engrafted and appeared to protect healthy blood cells during treatment.
9:13 AMScienceDaily
COVID-19 activity has increased across parts of the United States, raising concern about a summer surge. The trend reflects renewed transmission even as the virus remains less disruptive than during earlier pandemic waves.
1:55 PMAirguide Info6:16 PMAl Jazeera
DR Congo’s Ebola outbreak spreads to two new health zones, WHO says
Summary
Ebola cases have been detected in two additional health zones in the Democratic Republic of the Congo, including border areas of South Ubangi and Haut-Uele. Health workers are struggling to contain the spread.
The outbreak's movement into additional and border-adjacent zones expands the geographic challenge for response teams.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Expansion into border regions raises the risk of further spread and makes a fragmented response more difficult.
10:39 AMStat News
Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
Summary
The opinion argues that FDA commissioner nominee Heidi Overton is mishandling the scientific evidence surrounding mifepristone. It frames her appointment as placing new leadership over a long-running dispute about the abortion medication.
The central issue is whether the FDA’s handling of mifepristone will remain grounded in its
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The dispute could test whether reproductive drug regulation follows scientific review or shifts with political leadership.
9:32 AMStat News
STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
Summary
The roundup covers Senate questioning of President Trump’s FDA commissioner nominee on China, vaccines, and abortion access. It also points to a Novo Nordisk deal and other health policy and pharmaceutical news.
The nominee’s testimony puts the FDA’s future direction under scrutiny on issues that directly affect
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The confirmation process could determine whether the FDA’s next phase emphasizes regulatory continuity or political intervention.
8:53 AMStat News
Federal judge rolls back landmark disability protections
Summary
A federal judge rolled back landmark protections favoring community-based living and services for people with disabilities. The Justice Department said in June that it would stop enforcing laws that prioritize community settings over nursing homes.
The decisive change is reduced federal enforcement of a framework designed to prevent unnecessary institutionalization.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The ruling could weaken a major legal safeguard for independent living and reshape how disability services are funded and delivered.
8:51 AMCNBC
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s
Summary
Novo Nordisk is trying to regain momentum as Eli Lilly strengthens its position in the GLP-1 obesity-drug market. Analysts point to Lilly's advantages as a reason it may remain ahead while Novo seeks a turnaround.
The competitive shift is moving beyond demand for weight-loss drugs to execution, product advantages, and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The rivalry will shape access, pricing, and the direction of one of the pharmaceutical industry's most valuable markets.
5:58 AMCNBC
Pharma stock soars 150% on injectables deal with Wegovy maker Novo
Summary
Shares of Swedish drug-delivery company Nanexa rose more than 150% after it announced a licensing agreement with Novo Nordisk. The deal gives Novo access to Nanexa's injectable drug-delivery technology.
The market reaction reflects the value investors place on technologies that could improve injectable medicines,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Drug-delivery technology can affect dosing, convenience, and product differentiation, making small platform companies strategically important to large pharmaceutical manufacturers.
5:11 AMMarketWatch
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Summary
Novo Nordisk struck a licensing deal valued at more than $1 billion days after its capital-markets day disappointed investors. The agreement sent shares of the Swedish partner sharply higher and offered Novo a new strategic asset.
The deal gives Novo a concrete action after investors questioned its next phase of growth.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Novo needs deals that translate into stronger products and growth, not just announcements that temporarily ease pressure on its stock.
11:25 AMStat News
STAT+: Lilly wins approval for once-weekly insulin shot
Summary
The FDA approved Eli Lilly's Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It offers an alternative to daily long-acting insulin injections.
Weekly dosing could reduce the treatment burden that causes some patients to delay or miss
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A weekly option could improve adherence and broaden choices for adults who need basal insulin.
9:13 AMScienceDaily
CRISPR could help doctors attack blood cancer without destroying healthy cells
Summary
Researchers edited donor stem cells to remove CD33, a protein also targeted by some blood cancer treatments. In a 30-patient trial, the modified cells engrafted and appeared to protect healthy blood cells during treatment.
The key shift is that gene editing may separate the cancer target from the healthy
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The strategy could make powerful blood cancer treatments safer and expand options for patients with aggressive disease.
1:55 PMAirguide Info
Is There a Summer COVID Surge? What Rising Cases Mean in 2026
Summary
COVID-19 activity has increased across parts of the United States, raising concern about a summer surge. The trend reflects renewed transmission even as the virus remains less disruptive than during earlier pandemic waves.
Rising case activity means health systems and vulnerable people may face another seasonal increase in
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A summer increase could add pressure to healthcare systems and renew attention on protection for older and medically vulnerable people.
Other Developments
A curated list of other prominent stories from this day.
University Hospital at Downstate is piloting an ambient AI scribe with 50 physicians in family medicine, internal medicine, cardiology and emergency care. The tool has drafted notes for more than 900 patient encounters since May.
7:17 PMPYMNTS
Walmart says it will keep expanding affordable and convenient health and wellness products and services as it marks the 20th anniversary of its $4 generic prescription program. The retailer says the program has generated substantial savings for U.S. customers over two decades.
4:23 PMPYMNTS
Oura is preparing for a Nasdaq IPO that will position the company as more than a smart-ring maker. It is using sleep, heart rate, temperature and stress data to deliver personalized health guidance, including new women's health features.
3:25 PMPYMNTS
A U.N.-backed agency signed sublicensing agreements covering generic versions of Roche's influenza treatment. The deals are intended to support pandemic preparedness by enabling additional manufacturers to produce the medicine.
1:50 PMStat NewsCuts to NIH funding delayed a clinical trial for children with diffuse intrinsic pontine glioma, a deadly brain tumor with few treatment options. The delay cost patients time in a disease where treatment opportunities are limited.
12:43 PMCNBC
The report tracks recent hires, departures, promotions, and transfers across the pharmaceutical industry. It presents the changes as a personnel roundup rather than a single corporate development.
9:38 AMStat News
A large analysis estimates that Phelan-McDermid syndrome may affect about one in 7,300 people, including more than 45,000 Americans. Researchers say many cases likely go undiagnosed because patients do not routinely receive genetic testing, even as targeted treatments enter clinical trials.
9:32 AMScienceDailyWith the 2026 fiscal year nearing its end, lawmakers are pressing the health department to spend $100 million Congress allocated for teen pregnancy prevention. The funds remain unused despite the program's federal authorization.
4:40 AMNPR Politics
The authors argue that debating whether someone died with measles or of measles focuses too narrowly on the final event rather than the broader chain of illness and vulnerability.
4:30 AMStat News
Denys T. Lau and Jennifer D. Schoendorf argue that differences between federal and state methods for determining measles deaths will make the official toll harder for the public to understand.
4:30 AMStat News
The Advanced Research Projects Agency for Health is planning a research program on autism across the lifespan, led by Russell Shilling, a former Iraq War officer and Sesame Street contributor.
4:30 AMStat News
At least five candidates are competing to become the next director-general of the World Health Organization, which faces major challenges and uncertainty over the future of U.S. engagement.
4:30 AMStat News
Virtually all of the 175,000 public comments submitted on the FDA's 2022 proposal to ban menthol cigarettes were form letters that echoed tobacco-industry arguments.
4:30 AMStat News
Walmart heiress Alice Walton is directing part of her fortune toward Arkansas health care, including a tuition-free medical school and a planned $350 million hospital investment.
3:02 AMFortunePharmaceutical companies are pursuing a wave of increasingly complex mergers, while competition concerns and patent disputes create additional legal obstacles. The deals reflect pressure to secure valuable drug assets and strengthen market positions.
12:00 AMFinancial Times7:17 PMPYMNTS
Doctors Stop Typing as AI Takes Over the Chart
Summary
University Hospital at Downstate is piloting an ambient AI scribe with 50 physicians in family medicine, internal medicine, cardiology and emergency care. The tool has drafted notes for more than 900 patient encounters since May.
The pilot shifts AI documentation from demonstration to routine use across several clinical departments. Physicians
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Ambient documentation could reduce physician administrative load while creating new risks around accuracy, privacy and clinical liability.
4:23 PMPYMNTS
Walmart Vows Continued Expansion of Health and Wellness Reach
Summary
Walmart says it will keep expanding affordable and convenient health and wellness products and services as it marks the 20th anniversary of its $4 generic prescription program. The retailer says the program has generated substantial savings for U.S. customers over two decades.
Walmart is treating low-cost pharmacy access as a platform for a broader healthcare strategy, using
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A larger Walmart health offering could make the retailer an increasingly important competitor in consumer healthcare access.
3:25 PMPYMNTS
Oura’s IPO Puts AI-Powered Healthcare on the Ticker
Summary
Oura is preparing for a Nasdaq IPO that will position the company as more than a smart-ring maker. It is using sleep, heart rate, temperature and stress data to deliver personalized health guidance, including new women's health features.
The IPO will test whether investors value consumer wearables as healthcare platforms rather than hardware
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Oura's market debut could influence how investors price the broader business of turning continuous consumer health data into medical insight.
1:50 PMStat News
STAT+: Licensing deals on generic versions of Roche flu drug aimed at preparing for pandemic
Summary
A U.N.-backed agency signed sublicensing agreements covering generic versions of Roche's influenza treatment. The deals are intended to support pandemic preparedness by enabling additional manufacturers to produce the medicine.
The agreements shift preparedness from dependence on a single branded supplier toward a broader manufacturing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
More potential suppliers could reduce shortages and improve access to antiviral treatment during a future influenza pandemic.
12:43 PMCNBC
NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn't have
Summary
Cuts to NIH funding delayed a clinical trial for children with diffuse intrinsic pontine glioma, a deadly brain tumor with few treatment options. The delay cost patients time in a disease where treatment opportunities are limited.
The case turns an abstract funding reduction into a direct clinical consequence: research stalled while
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Delays in rare pediatric cancer research can impose an irreversible cost on patients who cannot afford to wait for institutions to resolve budget disputes.
9:38 AMStat News
STAT+: Up and down the ladder: The latest comings and goings
Summary
The report tracks recent hires, departures, promotions, and transfers across the pharmaceutical industry. It presents the changes as a personnel roundup rather than a single corporate development.
The immediate shift is in who holds decision-making roles across drug companies, though the available
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Leadership changes can redirect drug pipelines and partnerships even when they do not produce immediate policy or market news.
9:32 AMScienceDaily
This “rare” autism-linked genetic disorder may be far more common than scientists thought
Summary
A large analysis estimates that Phelan-McDermid syndrome may affect about one in 7,300 people, including more than 45,000 Americans. Researchers say many cases likely go undiagnosed because patients do not routinely receive genetic testing, even as targeted treatments enter clinical trials.
The new prevalence estimate challenges the disorder’s classification as exceptionally rare and points to a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Better detection could shift Phelan-McDermid syndrome from an overlooked condition into a larger clinical and drug-development priority.
4:40 AMNPR Politics
Congress passed $100 million for teen pregnancy prevention. Most of it is untouched
Summary
With the 2026 fiscal year nearing its end, lawmakers are pressing the health department to spend $100 million Congress allocated for teen pregnancy prevention. The funds remain unused despite the program's federal authorization.
The immediate problem is not a lack of funding but a failure to deploy it
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Unspent appropriations can weaken prevention efforts and undermine confidence in the federal health department's ability to execute programs Congress funds.
4:30 AMStat News
Opinion: The ‘died with’ vs. ‘died of’ measles discussion misses something very important
Summary
The authors argue that debating whether someone died with measles or of measles focuses too narrowly on the final event rather than the broader chain of illness and vulnerability.
A binary cause-of-death argument can obscure how measles interacts with underlying conditions and contributes to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
How officials classify deaths shapes risk perception, vaccine policy, and the public's understanding of measles harm.
4:30 AMStat News
Opinion: RFK Jr.’s use of the National Center for Health Statistics will add confusion to measles deaths count
Summary
Denys T. Lau and Jennifer D. Schoendorf argue that differences between federal and state methods for determining measles deaths will make the official toll harder for the public to understand.
Using competing federal and state definitions could produce multiple credible-looking measles death counts instead of
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Public health decisions depend on comparable mortality data, especially during a resurging outbreak.
4:30 AMStat News
STAT+: The head of Kennedy’s new autism project has roots in Iraq War, Sesame Street
Summary
The Advanced Research Projects Agency for Health is planning a research program on autism across the lifespan, led by Russell Shilling, a former Iraq War officer and Sesame Street contributor.
The project signals a federal push toward long-term autism research that spans childhood, adulthood, and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A large federal autism program could redirect research funding for years, making its design and accountability consequential.
4:30 AMStat News
At least five candidates vie to become the next WHO leader, as questions over U.S. role loom
Summary
At least five candidates are competing to become the next director-general of the World Health Organization, which faces major challenges and uncertainty over the future of U.S. engagement.
The leadership contest will determine how the WHO handles pressure on its funding, authority, and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The next WHO leader may have to rebuild authority while managing a potentially weaker relationship with its most influential member.
4:30 AMStat News
How Big Tobacco flooded the FDA with public comments to kill a menthol cigarette ban
Summary
Virtually all of the 175,000 public comments submitted on the FDA's 2022 proposal to ban menthol cigarettes were form letters that echoed tobacco-industry arguments.
The comment count overstated grassroots opposition and gave regulators a distorted picture of public sentiment.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Manufactured public input can influence health rules even when it does not reflect independent public opinion.
3:02 AMFortune
Alice Walton got $33 billion richer last year without running a company. She’s building a tuition-free medical school instead
Summary
Walmart heiress Alice Walton is directing part of her fortune toward Arkansas health care, including a tuition-free medical school and a planned $350 million hospital investment.
Walton's spending could expand Arkansas's physician pipeline and hospital capacity without relying entirely on public
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Private wealth is reshaping health care infrastructure in Arkansas, with benefits and priorities tied to a single donor's choices.
12:00 AMFinancial Times
Pharma deal fever boosts flurry of highly complex mergers
Summary
Pharmaceutical companies are pursuing a wave of increasingly complex mergers, while competition concerns and patent disputes create additional legal obstacles. The deals reflect pressure to secure valuable drug assets and strengthen market positions.
The deal surge is colliding with tougher scrutiny over market concentration and intellectual property rights.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The mergers could reshape drug competition, but regulatory and patent challenges may delay deals or reduce their value.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!